Publication 

Key Points

  • 47% of perioperative anaphylaxis cases were attributed to antibiotic use
  • Teicoplanin, a glycopeptide antibiotic, implicated in 38% cases of antibiotic-induced anaphylaxis (1/6 total perioperative cases)
  • 1/3 of anaphylaxis cases attributed to neuromuscular blockers
  • 40/266 anaphylaxis cases reviewed involved cardiac arrest and 10 deaths

Publication

Key Points

  • 89% of untreated infants with congenital cytomegalovirus (cCMV) infection and isolated sensorineural hearing loss (SNHL) develop significant bilateral hearing loss
  • In valganciclovir treated cohort, only 35% of cCMV w/ isolated SHNL had functional hearing loss after 4-5y
  • No deterioration of unaffected ears observed in treated cohort

Publication

Key Points

  • 78.8% decrease in childhood buprenorphine-naloxone exposures following transition to unit-dose packaging (UDP) from bulk packaging (pill bottle)
  • No decrease in single-entity buprenorphine exposures, which have not transitioned to UDP
  • Switching to UDP for single-entity buprenorphine products may lower future childhood buprenorphine exposure and hospitalization rates

fingolimod

The US FDA has approved fingolimod (Gilenya by Novartis) for the treatment of multiple sclerosis (MS) in children aged 10 years or older.

Key Points

  • Once-daily, taken orally
  • Inhibits lymphocyte migration to CNS (downregulates sphingosine receptor)
  • Approved since 2010 for relapsing MS in adults
  • Current first-line: Interferon beta/glatiramer acetate injections (off-label in pediatric MS)